ChineseInvestors.com, Inc. (CIIX) Subsidiary Expands Sales Force to Grow Division’s Domestic Revenues

• ChineseInvestors.com is the foremost financial information website for Chinese-speaking investors


• The company provides premier, real-time market commentary, analysis and educational services in the Chinese language


• ChineseInvestors.com’s wholly owned subsidiary is ChineseHempOil.com, Inc.

California-based ChineseInvestors.com, Inc. (OTCQB: CIIX) operates the foremost financial information website for Chinese-speaking investors. A fintech company, ChineseInvestors.com provides online financial information in Chinese language character sets. This includes traditional and simplified character sets. This financial information is for the Chinese population in the United States and around the world. The company’s subscriber base includes free as well as paying members, mainly located in the United States and Canada.

The emphasis today is on companies that can provide first-rate information that brings greater transparency to investors. The CFA Institute (http://ibn.fm/DdDTx) states that “the use of data and technology can result in a more effective and efficient overall financial reporting process in which investors… receive more transparent, better-quality information on a timely basis.”

ChineseInvestors.com works to provide better-quality information by focusing on making available premier, real-time market commentary, analysis and educational services in the Chinese language. A premier financial information company, its services are primarily delivered to U.S. public and private companies and U.S. residents and citizens. In addition, the company’s focus is on providing advertising and public relations-related support services, helping companies to better link to the large and growing Chinese community.

ChineseInvestors.com’s wholly owned subsidiary is ChineseHempOil.com, Inc., which offers CBD (cannabidiol) oil and hemp oil products. This subsidiary has expanded its domestic sales force and has appointed Nina Wang as its vice president of sales for its United States Consumer Retail/E-Commerce Division. This furthers the process to complete the spinoff of all of ChineseInvestors.com’s hemp-related assets. Wang joined ChineseHempOil.com in March of this year. Since then, she has hired a team of sales representatives centered on wholesale and consignment sales in the Los Angeles area.

In a news release, Warren Wang, ChineseInvestors.com’s chief executive officer, said, “With over 15 years sales and management experience, we look forward to the increased sales that will be generated through Mrs. Wang’s leadership as we are laying the groundwork to increase revenues in advance of the spin-off of all of the Company’s hemp related assets.”

Wang has more than 15 years’ sales experience in the financial services industry. She has over 10 years of experience as a merchant services sales manager at USA First Credit Card, Inc. Before that, she worked as a sales manager for Alliance Bank Card Services.

The spin-off of all of ChineseInvestors.com’s hemp-related assets was originally scheduled for May 31, 2018. The spin-off has been temporarily postponed as the company continues to develop its domestic sales channels.

For more information, visit the company’s website at www.ChineseInvestors.com

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Earth Science Tech, Inc. (ETST) Eyes Future Uplisting to OTCQB Venture Market

• ETST issues new audio press release regarding its audits, Form 10, financing plans and fully reporting status


• ETST has started 2017 fiscal year audit, which is required, along with the approved Form 10, to uplist to the OTCQB Venture Market


• Biotech company is focused on developing medical devices for the pharmaceutical and nutraceutical fields and marketing its high-grade line of hemp cannabidiol (CBD)

Earth Science Tech, Inc. (OTC: ETST) recently released an audio press release discussing its future financial plans and its previously announced completion of audits and Form 10 submission, which could lead to an uplisting to the OTCQB Venture Market (http://ibn.fm/JEWaC).

ETST has completed its audit for FY2015 and FY2016 and submitted its Form 10 to be fully reporting (http://ibn.fm/HDpTq), and it is currently conducting its audit for FY2017. That audit and the approved Form 10 submission, together, are needed for an uplisting to the OTCQB Venture Market.

ETST, a biotech company based in Doral, Florida, has repositioned its line of full-spectrum cannabidiol products. It also conducts R&D for low cost, non-invasive medical devices, as it concentrates on manufacturing, marketing and distributing its cannabinoid products to the nutraceutical and pharmaceutical markets.

Dr. Michel Aube, CEO and chief science officer of ETST, said that transparency is a key tool in the expansion of the company’s business and maintaining the confidence of investors. In a news release, he added, “Since all of our amazing projects are ongoing with our partners, investor confidence will grow, and we will be able to complete our first big round of financing.”

Nickolas Tabraue, director and president of ETST, said, “Thanks to our passionate, likeminded team, the transition should be smooth as we continue growing. I look forward to sharing updates on the full reporting process as it progresses.”

ETST holds four wholly owned subsidiaries. Cannabis Therapeutics is an emerging biotechnology company. KannaBidioiD manufactures and distributes in the recreational sector. Earth Science Foundation, Inc. is becoming a non-profit to accept grants and donations for conducting additional studies. Earth Science Pharmaceutical develops medical diagnostic tools and vaccines.

For more information, visit the company’s website at www.EarthScienceTech.com

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) Inks Option Agreement to Acquire Licensing Rights to TriVair™ Drug Delivery System

Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) this morning announced that it has signed an option agreement with IP Med Inc. to obtain an exclusive worldwide license for Trivair™ Nasal and Pulmonary Breath-Propelled Drug Delivery Systems™ for the delivery of Pivot’s patented Ready-To-Infuse-Cannabis (“RTIC”) cannabinoid products. The option expires in six months during which time Pivot will determine compatibility with its RTIC powder formulations and decide whether to enter into a definitive licensing agreement. “Pivot continues to grow its portfolio of patented technologies specifically for the formulation and delivery of cannabinoids. We are very excited about the unique opportunity this differentiated product presents for patients seeking an alternative method to traditional cannabis practices. Upon the completion of our compatibility testing, Pivot will have the world’s first nasal and pulmonary powdered cannabis device for quick onset and use in the medical field. This combination product may be well suited for managing such indications as sleep disorder, migraine, late-stage cancer pain, and address opioid withdrawal,” Pivot Pharmaceuticals Chief Medical Officer Dr. Wolfgang Renz stated in the news release.

To view the full press release, visit http://ibn.fm/Kj0Ij

About Pivot Pharmaceuticals Inc.

Pivot Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies. Pivot’s wholly owned medical cannabis products division, Pivot Green StreamHealth Solutions Inc. (“PGS”), conducts research, development and commercialization of cannabinoid-based nutraceuticals and pharmaceuticals. PGS has acquired worldwide rights to “RTIC” Ready-To-Infuse Cannabis powder to oil technology, BiPhasix™ Transdermal Drug Delivery platform technology (topical), Solmic Solubilisation technology (oral) and Thrudermic Transdermal Nanotechnology (transdermal) for the delivery and commercialization of cannabinoid, cannabidiol, and tetrahydrocannabinol-based products. PGS’ initial product development candidates will include topical treatments for women’s sexual dysfunction (PGS-N005), as well as psoriasis (PGS-N007), and an oral product (PGS-N001) for cancer supportive care. For more information, visit the company’s website at www.PivotPharma.com.

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Victory Square Technologies Inc. (CSE: VST) (OTC: VSQTF) (FRANKFURT: 6F6) (WKN: A2AKL8) Portfolio Company Closes Private Placement

Victory Square Technologies (CSE: VST) (OTC: VSQTF) (FRANKFURT: 6F6) (WKN: A2AKL8) this morning announced that a portfolio company that it incorporated earlier this year, FansUnite Entertainment Inc., has raised $4,457,750 CAD in a private placement financing. FansUnite raised capital in accordance with its strategy to maximize shareholder value, which includes going public in the fourth quarter of 2018. As a result of the private placement, Victory Square’s interest in FansUnite has decreased from 100% to 48.55%. “We’re extremely pleased with the impressive oversubscription of the FansUnite private placement,” Victory Square CEO Shafin Diamond Tejani stated in the news release. “FansUnite is utilizing blockchain technology in an industry ripe for growth and have the opportunity to build a protocol that can significantly change the landscape of the sports betting and sports data industries.”

To view the full press release, visit http://ibn.fm/4PdMM

About Victory Square Technologies Inc.

Victory Square Technologies is a blockchain-focused venture builder that funds and empowers entrepreneurs to implement innovative blockchain solutions. Victory Square portfolio companies are disrupting every sector of the global economy including Virtual Reality, Artificial Intelligence, Personalized Health, Gaming and Film. Victory Square has a proven process for identifying game-changing entrepreneurs and providing them with the partners, mentorship and support necessary to accelerate their growth and help them scale globally. For more information, please visit www.VictorySquare.com.

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Pressure BioSciences Inc.’s (PBIO) Recently Acquired PreEMT™ Platform Enhances Development of Biotherapeutic Protein Drugs

• Biologics offer novel ways of treating degenerative diseases like Alzheimer’s


• Biologics are one of the fastest-growing drug categories


• PreEMT™ technology improves quality, reduces cost of biologic manufacture

When we think of drugs, an image of potions in round-bottom flasks conjured up in labs comes to mind, or perhaps pills of one sort or another ingested with a sip of water, for about 90 percent of drugs currently in use have that profile. However, discovering that the human body will act as its own physician by dispensing protective proteins called antibodies to fight the toxins that bring on diseases has spurred efforts, naturally enough, to develop those proteins synthetically. This new class of biotherapeutic protein drugs, or biologics, tends to be more effective at combating pathological conditions with less side effects, since they mimic endogenously produced proteins, which target highly specific parts of the invader (antigens). Unfortunately, the production of biologics is easier said than done; it typically requires hundreds of process steps to assemble one of these complex biotherapeutic proteins. Therefore, it should come as no surprise that the PreEMT™ platform recently acquired by Pressure BioSciences Inc. (OTCQB: PBIO) is a welcome addition to biologic development.

The company recently announced the signing of an agreement with an international biopharmaceutical company to assess the potential of the PreEMT™ technology as the basis for a unique manufacturing process and as an enhancement to the quality of a key protein-based drug currently under development (http://ibn.fm/X3R0O).

Many currently available drugs are synthesized chemically, with molecular structures that are “well defined and relatively simple” (http://ibn.fm/wL3eC). Their simplicity makes them easy to produce and easy for the human body to assimilate. A good example is acetylsalicylic acid (ASA), the active ingredient in aspirin, which has a molecular weight of about 180 grams per mole. Generally, such drugs are swallowed in pill or liquid form before entering the gastrointestinal system and blood stream by diffusion through the intestinal wall. Once in the blood, they have access to the entire body, their tiny size allowing them to penetrate cell membranes easily.

Biologics, by contrast, are much larger compounds that mimic the complex endogenous proteins produced by the immune system. They are generally composed of hundreds of amino acids and may carry a weight as high as 150,000 grams per mole. Biologics will bind to the specific cell receptors associated with a particular disease. For example, monoclonal antibodies are adept at recognizing very specific structures on the surface of cells. This specificity means that healthy cells are not adversely affected, resulting in less side effects. This is one reason that treatment by biologics can be superior to regimens developed with traditional combinatorial chemistries.

Because of their complexity, the manufacture of biotherapeutic proteins is prone to errors, very often falling prey to aggregation and misfolding. Misfolding occurs when the normal, three-dimensional structure of a protein becomes distorted, which may lead the protein to aggregate, a result that is quite the opposite of the benign outcomes intended in the manufacture of biologics. Many pathological conditions occur naturally by misfolded proteins. The list includes Alzheimer’s disease, which affects about 10 percent of the adult population over 65 years old in North America, as well as Parkinson’s disease and Huntington’s disease. However, PBIO’s PreEMT patented technology could reduce the incidence of misfolding in manufacture.

“PreEMT results in the dissolution of protein aggregates, which may have a significant impact on the quality of protein drugs by improving protein activity, homogeneity, and stability, as well as by reducing undesirable immunogenic properties”, Dr. Alexander Lazarev, PBIO’s vice president of R&D, stated in a news release.

Richard T. Schumacher, president and CEO of PBIO, added “Importantly, should the PreEMT technology result in more efficient production of high quality protein-based therapeutics for any biopharmaceutical company developing new protein-based therapeutics, manufacturing-scale licenses have the potential to generate millions of dollars in annual royalty revenue for PBIO.”

The technology is likely to find application across a wide range of proteins in reducing aggregation levels in bulk or final formulations, thereby improving product safety. PreEMT is scalable, and it is expected to significantly reduce manufacturing costs.

The acquisition of the PreEMT technology gives PBIO a footprint in the very large and growing biologics contract research services sector. The company is also busily developing its recently patented Ultra Shear Technology (UST) platform. The scalable, pressure-based UST technology creates stable nanoemulsions of otherwise immiscible fluids. It can be used to extend the shelf life of homogenized dairy products without refrigeration, for example. All the while, PBIO continues its focus on its core product line that generated $2.2 million in 2017 revenue: the development of pressure cycling technology (PCT)-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics and counter-bioterror applications.

For more information, visit the company’s website at www.PressureBioSciences.com

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Net Element’s (NASDAQ: NETE) Unified Payments Targets Multibillion-Dollar Events Industry with Integrated Payment Solution

• U.S. meetings and events industry generates more than $330 billion annually in direct spending and more than $845 billion in business sales


• Unified Payments’ solution significantly streamlines and simplifies event processing


• Solution enhances existing acceptance services with intelligent integration for point-of-sale systems, self-order kiosks, chargeback protection and multi-channel payment acceptance

In the United States, the meetings and events industry is continually expanding across all segments and is a driving force that supports almost six million jobs and pumps hundreds of billions of dollars into the nation’s economy. Recent data from the Events Industry Council indicates that this industry currently generates more than $330 billion in direct spending and over $845 billion in business sales annually.

Leading global technology and value-added solutions group Net Element, Inc. (NASDAQ: NETE) is establishing a foothold in this robust market with the launch of a brand new intelligent payment solution created specifically for the events industry.

Unified Payments, a subsidiary of Net Element, now offers a complete solution for event processing that enables merchants to maximize their sales, shorten their ticket lines and enhance the overall customer experience. The company’s unique solutions go into action the instant that ticket sales commence for an event, and the robust package offered by Unified Payments transforms event processing and makes it significantly simpler overall.

Unified Payments’ solution boosts existing acceptance services with intelligent integration for point-of-sale systems, self-order kiosks, chargeback protection and multi-channel payment acceptance. Program options like Fast Pass Funding, same-day funding, Zero Pay and the Complimentary Equipment Placement Program are offered to all events industry merchants throughout North America.

The Zero Pay program enables merchants to collect 100 percent of the sales revenue for their event through a cash payment discount for customers who pay by check, credit or debit card. This program includes free equipment rental, mobile point-of-sale, an optional e-commerce platform, same-day funding, an onsite technician and an analytics platform.

The Standard Plan offered to event merchants allows them to accept payments regardless of where a customer is located or how they are paying. With this plan, merchants can unify all payments and optimize the payment acceptance process. The Standard Plan includes free equipment rental, mobile point-of-sale, self-order kiosks, an optional e-commerce platform, an onsite technician, same-day funding and an analytics platform.

The feature-rich payment acceptance solutions now made available for event managers and merchants through Net Element and Unified Payments have the potential to revolutionize the way event transactions are processed. Additional information can be found at http://ibn.fm/6j5zR.

For more information, visit the company’s website at www.NetElement.com

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – JGR Capital Initiates Coverage on Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX)

Independent equity research firm JGR Capital this morning announced that it has initiated coverage on Foresight Autonomous Holdings (NASDAQ: FRSX) (TASE: FRSX), an innovator in automotive vision systems. Among other highlights, JGR noted that the company is operating in a rewarding market, as the demand for Advanced Driver Assistance System (“ADAS”) is anticipated to increase over the next decade. Also cited in the report were Foresight’s efforts to diversify by seeking international opportunities and leveraging its opportunities within the rail industry, as well as its ability to rapidly develop automotive vision solutions for ADAS and semi/fully autonomous vehicles.

To view the full report, visit http://ibn.fm/xmmKy

To view the full press release, visit http://ibn.fm/CBZPM

About Foresight

Foresight Autonomous is an Israel-based automotive technology company engaged in the design, development, and commercialization of stereo/quad-camera vision systems based on three-dimensional (3D) video analysis, advanced algorithms and artificial intelligence for image processing and sensor fusion. FRSX develops systems for accident prevention, which are designed to provide real-time information about a vehicle’s surroundings while in motion. The company targets two vertical markets, advanced driver assistance systems (“ADAS”) and autonomous/semi-autonomous vehicles, with its two key products of Eyes-On and QuadSight respectively. FRSX also develops and owns a cellular-based accident prevention system named Eye-Net. The company is headquartered in Ness Ziona, Israel. For more information, visit the company’s website at  www.ForesightAuto.com.

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html